Correction to: Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension (Advances in Therapy, (2018), 35, 6, (796-808), 10.1007/s12325-018-0718-9)

Suzuki K., Otsuka N., Hizaki H., Hashimoto M., Kuwayama Y., On behalf of the Tafluprost/Timolol Versus Latanoprost/Timolol (TTVLT) Study Group

2019
Advances in Therapy

View publication

Therapeutic Area

Glaucoma
Categories

Clinical development

Affiliations

Suzuki Eye Clinic, Yamaguchi, Japan; Santen Pharmaceutical Co., Ltd., Osaka, Japan; Fukushima Eye Clinic, Osaka, Japan

Related Publications

Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.

Efficacy and Safety of a Preservative-Free Latanoprost Cationic Emulsion in Patients with Open-Angle Glaucoma and Concurrent Ocular Surface Disease: A Randomized Phase 2 Study.

Bacharach, Jason; McLaurin, Eugene B.; Silverstein, Steven; Amrane, Mourad; Garrigue, Jean-Sebastien; Ismail, Dahlia; Flynn, William J.; Catiolanze Phase 2 study group

Assessment of Brain-Derived Neurotrophic Factor on Retinal Structure and Visual Function in Rodent Models of Optic Nerve Crush

Taniguchi T.; Sharif N.A.; Ota T.; Farjo R.A.; Rausch R.

View all Glaucoma publications